Long-term follow-up of the therapeutic outcomes for papillary thyroid carcinoma with distant metastasis

Medicine (United States)

Volumn 94, Issue 26, 2015, Pages

  Lin, Jen Der ^a   Hsueh, Chuen ^a   Chao, Tzu Chieh ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NECK; PRIMARY TUMOR; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL RATE; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BODY SCINTISCANNING; CARCINOMA; EPIDEMIOLOGY; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; TAIWAN; THYROID NEOPLASMS;

ADULT; AGED; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RISK FACTORS; TAIWAN; THYROID NEOPLASMS;

EID: 84942510805     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001063     Document Type: Article

References (28)

1. Dinneen SF, Valimaki MJ, Bergstralh EJ, et al. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab. 1995;80:2041-2045.
2. Lin JD, Huang MJ, Juang JH, et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid. 1999;9:1227-1235.
3. Ito Y, Higashiyama T, Takamura Y, et al. Clinical outcomes of patients with papillary thyroid carcinoma after the detection of distant recurrence. World J Surg. 2010;34:2333-2337.
4. Toniato A, Boschin I, Casara D, et al. Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol. 2008;15:1518-1522.
5. Lin JD, Chao TC, Chou SC, et al. Papillary thyroid carcinomas with lung metastases. Thyroid. 2004;14:1091-1096.
6. Hamzany Y, Soudry E, Strenov Y, et al. Early death from papillary thyroid carcinoma. Am J Otolaryngol. 2012;33:104-108.
7. Sobin LH, Wittekind Ch. (eds.) TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss; 2002: 52-56.
8. Delellis RA, Lloyd RV, Heitx PU, et al. Pathology and genetics of tumors of endocrine organs. In: World Health Organization of Tumours. Lyon: IARC; 2004: 73-76.
9. Zhang DD, Zhou XH, Freeman DH, et al. A non-parametric method for the comparison of partial areas under ROC curves and its application to large health care data sets. Stat Med. 2002;21:701-715.
10. Wang LY, Palmer FL, Nixon IJ, et al. Multi-organ distant metastases confer worse disease-specific survival in differentiated thyroid cancer. Thyroid. 2014;24:1594-1599.
11. Orita Y, Sugitani I, Matsuura M, et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery. 2010;147:424-431.
12. Ito Y, Kudo T, Kobayashi K, et al. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5, 768 patients with average 10-year follow-up. World J Surg. 2012;36:1274-1278.
13. Lin JD, Chao TC, Huang BY, et al. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine needle aspiration cytology. Thyroid. 2005;15:708-717.
14. Nilubol N, Zhang L, Kebebew E. Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. Thyroid. 2013;23:695-702.
15. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol. 2013;31:468-474.
16. Heikkilä A, Hagström J, Mäenpää H, et al. Loss of estrogen receptor beta expression in follicular thyroid carcinoma predicts poor outcome. Thyroid. 2013;23:456-465.
17. Bardet S, Malville E, Rame JP, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158:551-560.
18. Lang BH, Wong KP, Cheung CY, et al. Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis. Ann Surg Oncol. 2013;20:1329-1335.
19. Grogan RH, Kaplan SP, Cao H, et al. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery. 2013;154:1436-1446.
20. Yu GP, Li JC, Branovan D, et al. Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid. 2010;20:465-473.
21. Finlayson A, Barnes I, Sayeed S, et al. Incidence of thyroid cancer in England by ethnic group, 2001-2007. Br J Cancer. 2014;110:1322-1327.
22. Harari A, Li N, Yeh MW. Racial and socioeconomic disparities in presentation and outcomes of well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2014;99:133-141.
23. 131I-based detection on outcome. Endocr Relat Cancer. 2007;14:799-807.
24. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885.
25. 131I therapy for bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96:3078-3086.
26. Kim KM, Park JB, Bae KS, et al. Analysis of prognostic factors in patients with multiple recurrences of papillary thyroid carcinoma. Surg Oncol. 2012;21:185-190.
27. Blumhardt R, Wolin EA, Phillips WT, et al. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review. Endocr Relat Cancer. 2014;21:R473-R484.
28. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638-1644.